Healthy Tree Medical Secures Hundreds of Millions RMB in Series B Funding to Build Globally Leading Self-Administration Drug Delivery Solutions

VCBeat has learned that Suzhou Jiashu Medical Technology Co., Ltd. (“Jiashu Medical” or the “Company”) recently completed a Series B financing round worth hundreds of millions of yuan. The round was co-led by Hongshi Houfeng, a strategic partner of Huadong Medicine, and GL Ventures. Other investors included CLSA Capital, Haihe Asymchem Industrial Fund, Nanxi Biology, and Zhengwei Fund, while existing shareholders such as Xincheng Fund (affiliated with Innovent Biologics) and Triwise Capital made additional investments.

This financing round, led by strategic investors with industrial backgrounds and leading venture capital funds, will advance the R&D of the company’s product pipeline focused on self-administration devices, primarily auto-injectors; expand the automation, intelligence, and product delivery capabilities of its production lines; and accelerate the company’s global strategic layout.

Suzhou Jiashu Medical Technology Co., Ltd., established in 2018, is dedicated to providing comprehensive solutions for “advanced self-administration devices.” Since its inception, the company has launched multiple independently developed single-dose auto-injectors and multi-dose energy-storing auto-injectors. Having undergone freedom-to-operate (FTO) infringement analyses, it holds global intellectual property rights and offers self-administration solutions for various chronic conditions, including metabolic disorders and autoimmune diseases. Additionally, the company has independently developed high-speed production and assembly lines for auto-injectors, breaking the industry’s reliance on overseas manufacturing equipment. Its auto-injectors have entered the marketing authorization application stage alongside innovative drug products from several renowned pharmaceutical companies both in China and abroad.

In terms of its international business layout, Suzhou Jiashu Medical Technology Co., Ltd. is actively expanding its overseas channels and pharmaceutical enterprise clients, having achieved monthly deliveries exceeding one million units, with product quality receiving consistent acclaim from customers. In the future, the company will accelerate the digitalization of its manufacturing facilities, enhance ESG initiatives, manage its product quality system according to higher standards, and respond to customer needs more rapidly.

Mr. Xiong Changyan, Chairman of Jiashu MedicalStatement: We extend our sincere gratitude to the Series B investors and all existing shareholders for their trust and support. This financing round injects strong momentum into Jiashu Medical’s future rapid growth, propelling the company into a new stage of development in talent acquisition, product innovation and R&D, manufacturing facility construction, and global business expansion. Jiashu Medical will remain customer-centric, industry-focused, and product-driven, collaborating with domestic and international partners to jointly safeguard human health.

Mr. Wu Minfeng, Managing Partner of Hongshi HoufengStatement: Jiashu Medical is a leading enterprise in the field of self-administered drug delivery, with promising global market prospects. Hongshi Houfeng facilitated the signing of a strategic cooperation agreement between Huadong Medicine and Jiashu Medical, promoting deep collaboration between the two parties to jointly explore the global market. As a leading Chinese enterprise representing China in global competition within the advanced drug delivery sector, Jiashu Medical will receive long-term empowerment from its strategic investor, Hongshi Houfeng, growing together with the company.

Head of GL VenturesStatement: The management team of Jiashu Medical is highly experienced, with years of expertise in automated design, pharmaceutical formulation, supply chain management, and manufacturing. Through sustained R&D investment over the years, the team has successfully developed two core proprietary products: auto-injectors and cartridge-based energy storage pens, providing users with full-process services characterized by high stability, strong regulatory compliance, and timely delivery. We believe that under the leadership of the founding team, Jiashu Medical will continue to benefit a broad patient population and create value through the innovation and development of its self-administration device product pipeline.

Mr. Hu Baifeng, CLSA CapitalStatement: Jiashu Medical has been strategically positioned in the self-administration device sector for many years, dedicated to developing innovative products with patent barriers and global expansion capabilities. The company has successfully developed a dose-adjustable auto-injector pen, passed patent due diligence by leading industry clients both domestically and internationally, and rapidly entered global markets. CLSA Capital is optimistic about the management team’s ability, under the leadership of Xiong Changyan, to continue laying out innovative product pipelines, enhance production capacity, and capture market share. CLSA Capital will firmly support Jiashu Medical in further expanding its domestic and international markets and growing into a new-generation, globally competitive platform company for self-administration devices.

Mr. Yue Dazhou, Head of the Haihe Asymchem Industrial FundIt was stated that since its establishment in 2018, Suzhou Jiashu Medical Technology Co., Ltd. has focused on the field of self-administration, achieving remarkable results. The company has not only built independent intellectual property rights that break through multiple layers of foreign patent barriers but also gathered top industry talents. With profound industry insights and a comprehensive industrial chain layout, it precisely meets market demands. It is believed that this financing will inject strong momentum into the future development of Jiashu Medical, helping domestically produced self-administration devices benefit more patients at an earlier date.

Dr. Li Shang, Representative of Nanxi Biotechnology (Chief Investment Officer of Nuotai Biotechnology)Statement: Jiashu Medical has been deeply engaged in the field of self-administration devices for many years. Leveraging its interdisciplinary innovation capabilities, it has developed an adjustable-dose auto-injector pen with independent intellectual property rights and rapidly expanded into both domestic and international markets. We highly recognize the innovation planning, capacity expansion, and commercialization capabilities demonstrated by the management team under the leadership of Xiong Changyan, and will fully support its development into a new-generation platform enterprise for self-administration devices with international competitiveness.

Healthy Tree Medical Technology Co., Ltd. is committed to being a premier supplier of comprehensive self-administration device systems. Focusing on the diverse needs of the self-administration industry, the company provides multi-scenario services including self-administration solutions for high-viscosity drug formulations, personal emergency medication, autoimmune diseases, emergency management, and chronic disease management. As a global leading provider of total solutions for self-administration devices, Healthy Tree Medical adheres to its mission: “Professional and Dedicated, Trust in Healthy Tree!” to serve every customer and patient with excellence.

GL Ventures is one of the most active venture capital platforms in China, focusing on value discovery and value creation for innovative companies, with particular emphasis on key sectors such as new technologies, new energy, new materials, and new consumption. GL Ventures is committed to supporting the long-term development of early-stage innovative enterprises through systematic, in-depth value-creation services.

Hongshi Houfeng, co-founded by Mr. Wu Minfeng, a partner at CDH Investments, is a diversified alternative investment management firm deeply engaged in the healthcare sector and cross-border mergers and acquisitions. It maintains long-term, in-depth strategic collaborations with industrial partners such as Huadong Medicine, committed to promoting high-quality development in the biopharmaceutical industry.

CLSA Capital is a wholly-owned US dollar private equity investment platform of CITIC Securities. Established in 1995, CLSA Capital is a pioneer in private equity in Asia, with 30 years of industry experience. It serves over 200 global institutional investors, including pension funds, insurance companies, sovereign wealth funds, funds of funds, charitable foundations, endowment funds, family offices, and other professional investors.

Headquartered in Hong Kong, CLSA Capital has branches in Singapore, Tokyo, Seoul, Mumbai, and London. CLSA Capital is a member of CLSA, a renowned Asian capital markets and investment group. The parent company of CLSA is CITIC Securities (SSE: 600030, HKEX: 6030).

Established in 2024, the Haihe Asymchem Industry Fund leverages Asymchem’s robust industrial empowerment capabilities and forward-looking industry insights to strategically invest in biotechnology companies with leading technological advantages globally, supply chain enterprises at critical nodes of the biopharmaceutical industry chain, and synthetic biology companies with high growth potential. The fund is committed to becoming a long-term strategic partner deeply trusted by both industry players and capital investors.

Xincheng Fund was established in 2021, initiated and independently operated by Innovent Biologics Group. Currently, Xincheng Fund manages one venture capital fund—the Suzhou Xinhe Guoqing Fund. This venture capital fund was jointly initiated by Innovent Biologics and Yuanhe Holdings as general partners and is primarily operated by Innovent Biologics. The fund aims to actively implement the national innovation-driven development strategy, focus on frontier opportunities in the life and health industry, leverage industrial strength and distinctive advantages, and support the high-quality development of innovative enterprises. The fund specializes in investing in leading companies in innovative drugs, biotechnology, and related areas of the industry chain, with a particular emphasis on empowering next-generation biopharmaceuticals and breakthrough technologies to address unmet clinical needs.